Drug Addiction – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Drug Addiction – Pipeline Review, H1 2020’, provides an overview of the Drug Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Drug Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Drug Addiction

– The report reviews pipeline therapeutics for Drug Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Drug Addiction therapeutics and enlists all their major and minor projects

– The report assesses Drug Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Drug Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Drug Addiction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adjuvance Technologies Inc

Aelis Farma SAS

Amygdala Neurosciences Inc

Aphios Corp

Astellas Pharma Inc

Astraea Therapeutics LLC

BioCorRx Inc

Camino Pharma LLC

Cerevel Therapeutics LLC

Charleston Laboratories Inc

Chiesi Farmaceutici SpA

Consegna Pharma Inc

Curemark LLC

D&A Pharma SAS

Daya Drug Discoveries Inc

DD Therapeutics LLC

Denovo Biopharma LLC

Elysium Therapeutics Inc

Embera NeuroTherapeutics Inc

EncepHeal Therapeutics Inc

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals Co Ltd

IMV Inc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Kdac Therapeutics Inc

KemPharm Inc

Kinoxis Therapeutics Pty Ltd

Kyorin Pharmaceutical Co Ltd

MAKScientific LLC

MElkin Pharmaceuticals

Mind Medicine Inc

Mu Therapeutics Inc

NLS Pharma Group

Novartis AG

Omeros Corp

Orexigen Therapeutics Inc

Ovid Therapeutics Inc

P2D Inc

Paion AG

Protagenic Therapeutics Inc

Saniona AB

Sen-Jam Pharmaceutical LLC

Seropeutics LLC

Sosei Heptares

SpringWorks Therapeutics Inc

Tonix Pharmaceuticals Holding Corp

Vallon Pharmaceuticals Inc

Zelira Therapeutics Ltd

Zyla Life Sciences

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Drug Addiction – Overview

Drug Addiction – Therapeutics Development

Drug Addiction – Therapeutics Assessment

Drug Addiction – Companies Involved in Therapeutics Development

Drug Addiction – Drug Profiles

Drug Addiction – Dormant Projects

Drug Addiction – Discontinued Products

Drug Addiction – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Drug Addiction, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Drug Addiction – Pipeline by Adjuvance Technologies Inc, H1 2020

Drug Addiction – Pipeline by Aelis Farma SAS, H1 2020

Drug Addiction – Pipeline by Amygdala Neurosciences Inc, H1 2020

Drug Addiction – Pipeline by Aphios Corp, H1 2020

Drug Addiction – Pipeline by Astellas Pharma Inc, H1 2020

Drug Addiction – Pipeline by Astraea Therapeutics LLC, H1 2020

Drug Addiction – Pipeline by BioCorRx Inc, H1 2020

Drug Addiction – Pipeline by Camino Pharma LLC, H1 2020

Drug Addiction – Pipeline by Cerevel Therapeutics LLC, H1 2020

Drug Addiction – Pipeline by Charleston Laboratories Inc, H1 2020

Drug Addiction – Pipeline by Chiesi Farmaceutici SpA, H1 2020

Drug Addiction – Pipeline by Consegna Pharma Inc, H1 2020

Drug Addiction – Pipeline by Curemark LLC, H1 2020

Drug Addiction – Pipeline by D&A Pharma SAS, H1 2020

Drug Addiction – Pipeline by Daya Drug Discoveries Inc, H1 2020

Drug Addiction – Pipeline by DD Therapeutics LLC, H1 2020

Drug Addiction – Pipeline by Denovo Biopharma LLC, H1 2020

Drug Addiction – Pipeline by Elysium Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by Embera NeuroTherapeutics Inc, H1 2020

Drug Addiction – Pipeline by EncepHeal Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Drug Addiction – Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2020

Drug Addiction – Pipeline by IMV Inc, H1 2020

Drug Addiction – Pipeline by InterveXion Therapeutics LLC, H1 2020

Drug Addiction – Pipeline by Intra-Cellular Therapies Inc, H1 2020

Drug Addiction – Pipeline by Kdac Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by KemPharm Inc, H1 2020

Drug Addiction – Pipeline by Kinoxis Therapeutics Pty Ltd, H1 2020

Drug Addiction – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020

Drug Addiction – Pipeline by MAKScientific LLC, H1 2020

Drug Addiction – Pipeline by MElkin Pharmaceuticals, H1 2020

Drug Addiction – Pipeline by Mind Medicine Inc, H1 2020

Drug Addiction – Pipeline by Mu Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by NLS Pharma Group, H1 2020

Drug Addiction – Pipeline by Novartis AG, H1 2020

Drug Addiction – Pipeline by Omeros Corp, H1 2020

Drug Addiction – Pipeline by Orexigen Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by Ovid Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by P2D Inc, H1 2020

Drug Addiction – Pipeline by Paion AG, H1 2020

Drug Addiction – Pipeline by Protagenic Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by Saniona AB, H1 2020

Drug Addiction – Pipeline by Sen-Jam Pharmaceutical LLC, H1 2020

Drug Addiction – Pipeline by Seropeutics LLC, H1 2020

Drug Addiction – Pipeline by Sosei Heptares, H1 2020

Drug Addiction – Pipeline by SpringWorks Therapeutics Inc, H1 2020

Drug Addiction – Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020

Drug Addiction – Pipeline by Vallon Pharmaceuticals Inc, H1 2020

Drug Addiction – Pipeline by Zelira Therapeutics Ltd, H1 2020

Drug Addiction – Pipeline by Zyla Life Sciences, H1 2020

Drug Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H1 2020

Drug Addiction – Dormant Projects, H1 2020

Drug Addiction – Dormant Projects, H1 2020 (Contd..1), H1 2020

Drug Addiction – Dormant Projects, H1 2020 (Contd..2), H1 2020

Drug Addiction – Dormant Projects, H1 2020 (Contd..3), H1 2020

Drug Addiction – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Drug Addiction, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports